Alx Oncology Holdings (ALXO) Accumulated Depreciation & Amortization (2019 - 2026)
Alx Oncology Holdings recorded quarterly Accumulated Depreciation & Amortization of $100000.0 in Q1 2026, down 85.71% quarter-over-quarter from $700000.0 in Q4 2025, and down 50.0% year-over-year from $200000.0 in Q1 2025.
Alx Oncology Holdings' Accumulated Depreciation & Amortization history runs 8 years deep, the most recent figure standing at $100000.0 for Q1 2026.
- In Q1 2026, Accumulated Depreciation & Amortization fell 50.0% year-over-year to $100000.0; the TTM figure through Mar 2026 stood at $100000.0 (down 50.0% YoY), while the FY2025 annual figure was $700000.0, down 22.22% from the prior year.
- Accumulated Depreciation & Amortization came in at $100000.0 for Q1 2026 at Alx Oncology Holdings, down from $700000.0 in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $900000.0 in Q4 2024 to a low of $100000.0 in Q2 2022.
- A 5-year average of $382352.9 and a median of $300000.0 in 2022 frame the typical range for Accumulated Depreciation & Amortization.
- Across the five-year window, Accumulated Depreciation & Amortization soared 566.67% in 2022 and tumbled 50.0% in 2026, its largest moves.
- Alx Oncology Holdings' Accumulated Depreciation & Amortization stood at $300000.0 in 2022, then jumped by 166.67% to $800000.0 in 2023, then grew by 12.5% to $900000.0 in 2024, then retreated by 22.22% to $700000.0 in 2025, then plunged by 85.71% to $100000.0 in 2026.
- According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods registered $100000.0, $700000.0, and $600000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | 700,000.00 |
| Dec 31, 2025 | 700,000.00 |
| Sep 30, 2025 | 600,000.00 |
| Sep 30, 2025 | 600,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 900,000.00 |
| Dec 31, 2024 | 900,000.00 |
| Sep 30, 2024 | 700,000.00 |
| Sep 30, 2024 | 700,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | 200,000.00 |
| Mar 31, 2024 | 200,000.00 |
| Dec 31, 2023 | 800,000.00 |
| Dec 31, 2023 | 800,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Jun 30, 2023 | 400,000.00 |
| Jun 30, 2023 | 400,000.00 |
| Mar 31, 2023 | 200,000.00 |
| Mar 31, 2023 | 200,000.00 |
| Dec 31, 2022 | 300,000.00 |
| Dec 31, 2022 | 300,000.00 |
| Sep 30, 2022 | 100,000.00 |
| Sep 30, 2022 | 100,000.00 |
| Jun 30, 2022 | 100,000.00 |
| Jun 30, 2022 | 100,000.00 |
| Mar 31, 2022 | 200,000.00 |
| Mar 31, 2022 | 200,000.00 |
| Dec 31, 2021 | 63,000.00 |
| Dec 31, 2021 | 63,000.00 |
| Mar 31, 2021 | 30,000.00 |
| Mar 31, 2021 | 30,000.00 |
| Dec 31, 2020 | 200,000.00 |
| Dec 31, 2020 | 200,000.00 |
| Sep 30, 2020 | 100,000.00 |
| Sep 30, 2020 | 100,000.00 |
| Jun 30, 2020 | 100,000.00 |
| Jun 30, 2020 | 100,000.00 |
| Mar 31, 2020 | 100,000.00 |
| Mar 31, 2020 | 100,000.00 |
| Dec 31, 2019 | 400,000.00 |
| Dec 31, 2019 | 400,000.00 |
| Sep 30, 2019 | 300,000.00 |
| Sep 30, 2019 | 300,000.00 |
| Jun 30, 2019 | 200,000.00 |
| Jun 30, 2019 | 200,000.00 |